NASDAQ:NAGE • US1710774076
The current stock price of NAGE is 5.06 USD. Today NAGE is down by -0.78%. In the past month the price decreased by -1.36%.
ChartMill assigns a technical rating of 0 / 10 to NAGE.
ChartMill assigns a fundamental rating of 6 / 10 to NAGE. NAGE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
On March 4, 2026 NAGE reported an EPS of 0.03 and a revenue of 33.84M. The company beat EPS expectations (33.69% surprise) and beat revenue expectations (4.64% surprise).
11 analysts have analysed NAGE and the average price target is 16.12 USD. This implies a price increase of 218.5% is expected in the next year compared to the current price of 5.06.
For the next year, analysts expect an EPS growth of 67.17% and a revenue growth 20.36% for NAGE
Over the last trailing twelve months NAGE reported a non-GAAP Earnings per Share(EPS) of 0.18. The EPS increased by 80% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.38% | ||
| ROA | 20.82% | ||
| ROE | 28.91% | ||
| Debt/Equity | 0 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| KVUE | KENVUE INC | 16.32 | 34.967B | ||
| EL | ESTEE LAUDER COMPANIES-CL A | 30.09 | 34.679B | ||
| ELF | ELF BEAUTY INC | 23.09 | 4.874B | ||
| IPAR | INTERPARFUMS INC | 18.75 | 3.075B | ||
| COTY | COTY INC-CL A | 4.78 | 2.112B | ||
| BRBR | BELLRING BRANDS INC | 7.7 | 1.991B | ||
| EPC | EDGEWELL PERSONAL CARE CO | 8.36 | 985.792M | ||
| OLPX | OLAPLEX HOLDINGS INC | 13.79 | 977.902M | ||
| NATR | NATURES SUNSHINE PRODS INC | 24.57 | 452.2M | ||
| NUS | NU SKIN ENTERPRISES INC - A | 5.32 | 373.425M | ||
| USNA | USANA HEALTH SCIENCES INC | 8.96 | 332.696M | ||
| HNST | HONEST CO INC/THE | 36.67 | 328.412M |
View all stocks in the Personal Care Products Industry | View all stocks in the Consumer Staples Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 104 full-time employees. The company went IPO on 2007-06-25. At the center of its clinically proven product portfolio is Niagen (patented nicotinamide riboside or NR). Niagen powers its consumer supplement, Tru Niagen, a NAD+ boosting oral supplement in the United States, and Niagen Plus, featuring pharmaceutical-grade intravenous and injectable Niagen products. Its segments include Consumer Products, Ingredients, and Analytical Reference Standards and Services. Consumer Products segment provides finished dietary supplement products containing its proprietary ingredients directly to consumers and distributors, as well as NAD+ test kits exclusively to healthcare practitioners. Ingredients segment develops and commercializes proprietary-based ingredient technologies. Analytical Reference Standards and Services segment is focused on natural product fine chemicals, known as phytochemicals, and related research and development services.
NIAGEN BIOSCIENCE INC
10900 Wilshire Blvd Suite 600
Los Angeles CALIFORNIA US
Employees: 104
Phone: 13103886706
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 104 full-time employees. The company went IPO on 2007-06-25. At the center of its clinically proven product portfolio is Niagen (patented nicotinamide riboside or NR). Niagen powers its consumer supplement, Tru Niagen, a NAD+ boosting oral supplement in the United States, and Niagen Plus, featuring pharmaceutical-grade intravenous and injectable Niagen products. Its segments include Consumer Products, Ingredients, and Analytical Reference Standards and Services. Consumer Products segment provides finished dietary supplement products containing its proprietary ingredients directly to consumers and distributors, as well as NAD+ test kits exclusively to healthcare practitioners. Ingredients segment develops and commercializes proprietary-based ingredient technologies. Analytical Reference Standards and Services segment is focused on natural product fine chemicals, known as phytochemicals, and related research and development services.
The current stock price of NAGE is 5.06 USD. The price decreased by -0.78% in the last trading session.
NAGE does not pay a dividend.
NAGE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
11 analysts have analysed NAGE and the average price target is 16.12 USD. This implies a price increase of 218.5% is expected in the next year compared to the current price of 5.06.
NIAGEN BIOSCIENCE INC (NAGE) operates in the Consumer Staples sector and the Personal Care Products industry.
NIAGEN BIOSCIENCE INC (NAGE) has a market capitalization of 403.84M USD. This makes NAGE a Small Cap stock.